Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03758989 · ClinicalTrials.gov registry record · Phase 2

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

A Phase 2 study of DLBCL, sponsored by University of Rochester.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT03758989: Recruiting Phase 2 study of DLBCL, sponsored by University of Rochester.

NCT03758989 is a Phase 2 study of DLBCL that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 40 participants, below the 123-participant average among 14 other DLBCL trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03758989, a Phase 2 study of DLBCL, is actively recruiting participants, sponsored by University of Rochester.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future tool for response adapted therapy.

Conditions Studied

Interventions

  • DRUG Cyclophosphamide
  • DRUG Doxorubicin
  • DRUG Vincristine
  • DRUG Prednisone
  • DRUG Rituximab Prednisone

Study Locations (1)

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2019-05-08
Est. Completion 2027-06-01
Phase Phase 2
University of Rochester

636 total trials

What NCT03758989 shows while recruiting

NCT03758989 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 123-participant average among 14 other DLBCL trials with a reported enrollment target (67% lower).

The record links to 1 condition, with DLBCL appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT03758989 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03758989 about?

NCT03758989 is a clinical study titled "A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma". The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future ...

What is the current status of trial NCT03758989?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2019-05-08. Estimated completion is 2027-06-01.

What conditions does trial NCT03758989 study?

This clinical trial studies the following conditions: DLBCL.

What interventions are being tested in trial NCT03758989?

The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Vincristine (DRUG), Prednisone (DRUG), Rituximab Prednisone (DRUG).

Who is sponsoring clinical trial NCT03758989?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03758989 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for DLBCL

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03758989's enrollment target sits among peer trials

40 9th of 14 higher than 6 of 14 other DLBCL trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other DLBCL trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03758989, the US trial registry maintained by the National Library of Medicine. NCT03758989 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.